Why the study?
Current therapies for chronic heart failure remain limited, and the multi-target effects of Compound Fufangteng Oral Liquid across different CHF models remain unclear.
Does Compound Fufangteng Oral Liquid improve cardiac function and reduce myocardial damage in rat/mouse models of chronic heart failure?
Population
Rats/mice in three CHF models
Comparison
CFFOL vs blank control vs untreated model vs captopril
Design
Randomized unblinded animal study
Key result
Compound Fufangteng Oral Liquid significantly improved cardiac function, reduced serum NT-proBNP and inflammatory markers, and alleviated myocardial pathological changes in CHF animal models.
Authors
Loading...
Preclinical data support CFFOL efficacy in rodent CHF models; hypothesis-generating, clinical trials required before any human use.
Does Compound Fufangteng Oral Liquid improve cardiac function and reduce myocardial damage in rat/mouse models of chronic heart failure?
Compound Fufangteng Oral Liquid demonstrates cardioprotective effects and improves cardiac function across multiple preclinical models of chronic heart failure.
Lu et al. (2026) studied Chronic Heart Failure. Compound Fufangteng Oral Liquid (CFFOL) vs. Blank control, model, captopril was evaluated on Cardiac function (EF, FS), serum NT-proBNP, TNF-α, and myocardial enzymes. Compound Fufangteng Oral Liquid significantly improved cardiac function, reduced serum NT-proBNP and inflammatory markers, and alleviated myocardial pathological changes in CHF animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: